NCT04603807: An ongoing trial by Hoffmann-La Roche
This trial is ongoing. It must report results 3 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04603807 |
|---|---|
| Title | Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 30, 2021 |
| Completion date | June 26, 2028 |
| Required reporting date | June 26, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |